SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) presented new data from its Phase 2A clinical study of OPT-80 finding a 42% presence of the super toxin-producing strain of C. difficile known as BI/NAP1/027 strain and concluded that there was no significant difference in the overall cure rates with OPT-80 between subjects with the BI/NAP1/027 strain and subjects without the hypervirulent strain. Data was presented today at the 9th Biennial Congress of the Anaerobe Society of the Americas (Anaerobe 2008) in a poster titled “Typing and Susceptibility of Bacterial Isolates from the OPT-80 (PAR-101) Phase 2A Study for C. Difficile-Associated Diarrhea.”
